MAPK8 and cancer: We can qualitatively argue from our analysis that pharmaceutical intervention designed to inhibit JNK phosphorylation for suppressing cancer might result in prolonged enhancement of p38MAPK signaling which could consequently exceed a cellular threshold, worsening any pre-existing diabetic condition.